Jose M Rubio
Overview
Explore the profile of Jose M Rubio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Abi-Dargham A, Moeller S, Ali F, DeLorenzo C, Domschke K, Horga G, et al.
World Psychiatry
. 2023 May;
22(2):236-262.
PMID: 37159365
The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and providing individualized treatment recommendations. Here we review...
22.
Kane J, Mychaskiw M, Lim S, Suett M, Tian M, Rubio J
J Clin Psychiatry
. 2023 Apr;
84(3).
PMID: 37074300
Long-acting injectable antipsychotic agents (LAIs) are effective in schizophrenia relapse prevention but are often underutilized. This study aims to understand treatment patterns leading to a successful LAI implementation following schizophrenia...
23.
Kane J, Rubio J
Ther Adv Psychopharmacol
. 2023 Mar;
13:20451253231157219.
PMID: 36895432
No abstract available.
24.
Rubio J, Mychaskiw M, Lim S, Suett M, Wang Y, Tian M, et al.
J Clin Psychiatry
. 2023 Feb;
84(2).
PMID: 36791360
Long-acting injectable antipsychotic agents (LAIs) have improved clinical effectiveness and adherence versus oral antipsychotic agents (OAs); however, a minority of individuals with schizophrenia are treated with LAIs compared with OAs....
25.
Kane J, Chen A, Lim S, Mychaskiw M, Tian M, Wang Y, et al.
Int Clin Psychopharmacol
. 2023 Feb;
38(4):240-248.
PMID: 36752713
This study was designed to assess healthcare resource utilization (HCRU) and costs in patients with newly diagnosed schizophrenia based on timing and context of long-acting injectable antipsychotic agent (LAI) initiation....
26.
Sterling W, Sobolev M, Van Meter A, Guinart D, Birnbaum M, Rubio J, et al.
JMIR Form Res
. 2022 Nov;
6(11):e33676.
PMID: 36355414
Background: Digital technology has the potential to transform psychiatry, but its adoption has been limited. The proliferation of telepsychiatry during the COVID-19 pandemic has increased the urgency of optimizing technology...
27.
Rubio J, Perez-Rodriguez M
Schizophr Bull Open
. 2022 Oct;
3(1):sgac059.
PMID: 36277256
There is an ongoing debate about the potential risks and benefits of long-term antipsychotic treatment in schizophrenia. The data for and against the chronic use of these medicines is mostly...
28.
Solmi M, Croatto G, Piva G, Rosson S, Fusar-Poli P, Rubio J, et al.
Mol Psychiatry
. 2022 Aug;
28(1):354-368.
PMID: 35999275
Psychosocial interventions are recommended in schizophrenia and first-episode psychosis/early psychosis (EP). Nevertheless, literature is heterogeneous and often contradictory. We conducted an umbrella review of (network) meta-analyses of randomized controlled trials...
29.
Morales Martinez K, Munoz Garcia C, Figueroa Delgado A, Chavez Guitron L, Osorio Saravia D, Saavedra Montanez M, et al.
Exp Parasitol
. 2022 Aug;
240:108335.
PMID: 35932907
Parasite identification is crucial in areas where no sanitary inspection is conducted on fish, especially considering that parasitic zoonoses like anisakiasis and gnathostomiasis can pose a risk for human health....
30.
Soldevila-Matias P, Albajes-Eizagirre A, Radua J, Garcia-Marti G, Rubio J, Tordesillas-Gutierrez D, et al.
Rev Psiquiatr Salud Ment (Engl Ed)
. 2022 Jul;
15(2):101-116.
PMID: 35840277
Introduction: The neural correlates of the cognitive dysfunction in first-episode psychosis (FEP) are still unclear. The present review and meta-analysis provide an update of the location of the abnormalities in...